News|Articles|August 1, 2024

Biosimilars Month in Review: July 2024

The biosimilars month in review highlights recent FDA approvals and emphasizes new data demonstrating clinical equivalence and the potential impact on treatment options.

The biosimilars month in review highlights the US Food and Drug Administration (FDA) approvals of biosimilars for the treatment of rare diseases, ophthalmologic conditions, and rheumatic diseases. New data emphasize biosimilars' clinical equivalence to their reference products and highlight the potential impact on treatment options for patients living with these conditions.